R&D
Closed & Collaborative – January to February 2026
January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.
News
Roche's oral SERD flunks phase 3 breast cancer test
Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.
News
Servier snaps up cancer biotech Day One in $2.5bn deal
Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.
News
Zealand hit as Roche-partnered obesity drug disappoints
Shares in Zealand lost a third of their value today, after the biotech reported phase 2 data with Roche-partnered weight-loss therapy petrelintide.
News
Alnylam bets on Tenaya RNAi tech, and other licensing news
This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
